Legal
Companies that generate revenue less than $100 million would not have to undergo regular outside audits.
Johnson & Johnson has lost several major lawsuits over allegations that asbestos in its talcum powder contributes to ovarian cancer.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
Over and over there are reports about the increasing rise of antibiotic resistant bugs. Even as the number of resistant bacteria increases, the number of companies developing new types of antibiotics is decreasing.
The executives, convicted under the RICO Act, were found guilty of bribing prescribers and defrauding insurers in order to increase sales of Subsys, a powerful opioid pain killer intended for use with cancer patients.
Biopharma has several unique challenges, but one of them is the patent cliff. In an industry where only about one in 10 compounds actually makes it to market on average, those drugs aren’t able to stay on the market very long before their patents end and generic competition begins.
Days after the Federal Bureau of Investigation raided the offices of Bay Area-based uBiome over allegations of illegal billing practices, the company’s board of directors placed Jessica Richman and Zac Apte, the co-founders and co-chief executive officers of the company, on administrative leave.
The company disclosed the data breach in a filing with the U.S. Securities and Exchange Commission on Tuesday. The hacking occurred in March and the company said the data of about 1 percent of its total number of clients was compromised.
uBiome said it “does not have any control over physician billing. Any improper billing by physicians, if it occurred, is not related to uBiome’s billing practices,”
PRESS RELEASES